Urabe Akio
Division of Hematology, NTT Kanto Medical Center, 5-9-22 Higashi-gotanda, Shinagawa-ku, Tokyo 141-8625, Japan.
Gan To Kagaku Ryoho. 2003 Aug;30(8):1191-6.
Imatinib mesylate is an inhibitor of Bcr/Abl tyrosine kinase, which essentially participates the pathogenesis of chronic myelogenous leukemia (CML). Imatinib is highly effective in the treatment of CML. Because imatinib also inhibits c-kit and platelet-derived growth-factor (PDGF) receptor, it may be efficacious against some tumors which possess c-kit or PDGF receptors.
甲磺酸伊马替尼是一种Bcr/Abl酪氨酸激酶抑制剂，它在慢性髓性白血病（CML）的发病机制中起重要作用。伊马替尼在治疗CML方面非常有效。由于伊马替尼还抑制c-kit和血小板衍生生长因子（PDGF）受体，它可能对某些具有c-kit或PDGF受体的肿瘤有效。
